Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Chembiochem : a European Journal of Chemical Biology
|
August 30, 2014
Short antimicrobial lipo-α/γ-AA hybrid peptides
Yaqiong Li, Christina Smith, Haifan Wu, et al.
The Lancet. Psychiatry
|
September 18, 2025
Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines
Holly Christina Smith, Irene Petersen, Joseph F Hayes, et al.
Pilot and Feasibility Studies
|
August 10, 2021
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial
Sarah Scobie, Sue Jowett, Tosin Lambe, et al.
International Journal of Pediatric Otorhinolaryngology
|
May 17, 2026
Predicting and preventing tracheostomy risk in pediatrics: Development and pilot testing of a focused assessment tool
Rebecca Brooks, Pauline Chen, Romaine Johnson, et al.
Clinical Drug Investigation
|
September 29, 2012
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men
Gary Tong, Lorna Castaneda, Jun-Sheng Wang, et al.
Clinical Pharmacokinetics
|
September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Randy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.
British Journal of Clinical Pharmacology
|
May 24, 2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Clinical Therapeutics
|
March 3, 2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Nature Communications
|
July 17, 2021
Tetrasubstituted imidazoles as incognito Toll-like receptor 8 a(nta)gonists
Yi Yang, Adam Csakai, Shuangshuang Jiang, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
September 15, 2025
Identification of increased risk of perinatal anxiety: a multi-perspective qualitative study
Tamsin Fisher, Tom Kingstone, Noureen Asif Shivji, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Chembiochem : a European Journal of Chemical Biology
|
August 30, 2014
Short antimicrobial lipo-α/γ-AA hybrid peptides
Yaqiong Li, Christina Smith, Haifan Wu, et al.
The Lancet. Psychiatry
|
September 18, 2025
Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines
Holly Christina Smith, Irene Petersen, Joseph F Hayes, et al.
Pilot and Feasibility Studies
|
August 10, 2021
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial
Sarah Scobie, Sue Jowett, Tosin Lambe, et al.
International Journal of Pediatric Otorhinolaryngology
|
May 17, 2026
Predicting and preventing tracheostomy risk in pediatrics: Development and pilot testing of a focused assessment tool
Rebecca Brooks, Pauline Chen, Romaine Johnson, et al.
Clinical Drug Investigation
|
September 29, 2012
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men
Gary Tong, Lorna Castaneda, Jun-Sheng Wang, et al.
Clinical Pharmacokinetics
|
September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Randy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.
British Journal of Clinical Pharmacology
|
May 24, 2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Clinical Therapeutics
|
March 3, 2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Nature Communications
|
July 17, 2021
Tetrasubstituted imidazoles as incognito Toll-like receptor 8 a(nta)gonists
Yi Yang, Adam Csakai, Shuangshuang Jiang, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
September 15, 2025
Identification of increased risk of perinatal anxiety: a multi-perspective qualitative study
Tamsin Fisher, Tom Kingstone, Noureen Asif Shivji, et al.
Page
of 10